Skip to main content
. 2016 Mar 30;9(2):74–88. doi: 10.1111/cts.12390

Figure 1.

Figure 1

PKPD Continuum. phase 0/microdosing allows study of drug effects in the following domains: (I) – plasma PK; (II) – target PK; (III) – receptor binding and displacement; (IV) – pharmacological effects; biomarkers and/or clinical outcomes. PD, pharmacodynamics; PK, pharmacokinetics. Cu, concentration unbound in tissue; O, outcome; BM, biomarkers/metabolites; SEP, surrogate end points.